<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The sequelae of aortic root dilation are the lethal consequences of <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The root dilation is attributable to an imbalance between deposition of matrix elements and metalloproteinases in the aortic medial layer as a result of excessive transforming growth factor-beta signaling </plain></SENT>
<SENT sid="2" pm="."><plain>This study examined the efficacy and mechanism of <z:chebi fb="0" ids="35664">statins</z:chebi> in attenuating aortic root dilation in <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> and compared effects to the other main proposed preventative agent, <z:chebi fb="0" ids="6541">losartan</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS AND RESULTS: Marfan mice heterozygous for a mutant allele encoding a cysteine substitution in fibrillin-1 (C1039G) were treated daily from 6 weeks old with pravastatin 0.5 g/L or <z:chebi fb="0" ids="6541">losartan</z:chebi> 0.6 g/L </plain></SENT>
<SENT sid="4" pm="."><plain>The end points of aortic root diameter (n=25), aortic thickness, and architecture (n=10), elastin volume (n=5), dp/dtmax (maximal rate of change of pressure) (cardiac catheter; n=20), and ultrastructural analysis with stereology (electron microscopy; n=5) were examined </plain></SENT>
<SENT sid="5" pm="."><plain>The aortic root diameters of untreated Marfan mice were significantly increased in comparison to <z:mpath ids='MPATH_458'>normal</z:mpath> mice (0.161 ± 0.001 cm vs 0.252 ± 0.004 cm; P&lt;0.01) </plain></SENT>
<SENT sid="6" pm="."><plain>Pravastatin (0.22 ± 0.003 cm; P&lt;0.01) and <z:chebi fb="0" ids="6541">losartan</z:chebi> (0.221 ± 0.004 cm; P&lt;0.01) produced a significant reduction in aortic root dilation </plain></SENT>
<SENT sid="7" pm="."><plain>Both drugs also preserved elastin volume within the medial layer (pravastatin 0.23 ± 0.02 and <z:chebi fb="0" ids="6541">losartan</z:chebi> 0.29 ± 0.03 vs untreated Marfan 0.19 ± 0.02; P=0.01; <z:mpath ids='MPATH_458'>normal</z:mpath> mice 0.27 ± 0.02) </plain></SENT>
<SENT sid="8" pm="."><plain>Ultrastructural analysis showed a reduction of rough endoplasmic reticulum in smooth muscle cells with pravastatin (0.022 ± 0.004) and <z:chebi fb="0" ids="6541">losartan</z:chebi> (0.013 ± 0.001) compared to untreated Marfan mice (0.035 ± 0.004; P&lt;0.01) </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: <z:chebi fb="0" ids="35664">Statins</z:chebi> are similar to <z:chebi fb="0" ids="6541">losartan</z:chebi> in attenuating aortic root dilation in a mouse model of <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>They appear to act through reducing the excessive protein manufacture by vascular smooth muscle cells, which occurs in the Marfan aorta </plain></SENT>
<SENT sid="11" pm="."><plain>As a drug that is relatively well-tolerated for long-term use, it may be useful clinically </plain></SENT>
</text></document>